DNA Repair Drugs Market Size, Share and Trends Analysis Report, By Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), By Application (Ovarian cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast cancer, and Gastric cancer) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),Forecast (2022-2028)

The global DNA repair drug market is anticipated to grow at a significant CAGR 21%  during the forecast period (2022-2028). The increase in the prevalence of breast cancer has created potential demand for the development of DNA repair drugs, for its treatment which in turn drives the global DNA repair drugs market growth. In addition, leading pharmaceutical companies are focusing on the development of DNA drugs for breast cancer treatment.

Therefore, the market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of drugs for DNA repair drugs market is creating a strong and effective therapy.  For instance, in October 2019, the US Food and Drug Administration (FDA) has issued a Breakthrough Therapy Designation for niraparib provided by Janssen pharmaceuticalcompanies to treat patients with BRCA1 / 2 metastatic castration-resistant prostate cancer, its help to boots the market growth of DNA repair drug.

The governments in developing countries are investing heavily in modern Pharmaceutical infrastructure that may increase access to pharma sectors. Thus, government programs to increase cancer awareness and the growing spread in developing countries are leading to lucrative DNA repair drug market opportunities.

Market players are doing research and development to meet the rising demand for DNA repair drugs, such as Abbvie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and GlaxoSmithKline plc. are the key market players that are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches. For instance, in May 2019, Clovis Oncology, Inc., partnered with Bristol-Myers Squibb Company and Foundation Medicine Inc. initiating a phase II study to evaluate rucaparib in combination with nivolumab in patients with advanced serous carcinoma (HGSC) cancer or ovarian cancer of the endometrioid which helps to boost the growth of DNA repair drug market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Abbvie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and GlaxoSmithKline plc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global DNA Repair Drugs Market Report by Segment

By Drug Type

• Niraparib (Zejula)
• Olaparib (Lynparza)
• Rucaparib (Rubraca)
• Talazoparib (Talzenna)
• Others

By Application

• Ovarian cancer
• Fallopian Tube Cancer
• Peritoneal Cancer
• Breast cancer
• Gastric cancer

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global DNA Repair Drugs Market Report by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa